Assessment of 30-day all-cause mortality in metronidazole-treated patients with clostridium difficile infection

Scandinavian Journal of Infectious Diseases

Volumn 45, Issue 10, 2013, Pages 786-790

  Venugopal, Anilrudh A ^a,b   Szpunar, Susanna ^c   Sanchez, Kathryn ^a   Sessions, Robert ^a   Johnson, Leonard B ^a,b  

^a Division of Infectious Diseases   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Clostridium difficile; Guidelines; Metronidazole; Mortality; Severity

Indexed keywords

METRONIDAZOLE; RIFAXIMIN; VANCOMYCIN;

AGED; ARTICLE; CAUSE OF DEATH; CLINICAL ASSESSMENT; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RECURRENCE RISK; RECURRENT INFECTION; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84884391954     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2013.796087     Document Type: Article

References (16)

1. Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al . A predominantly clonal multi-institutional outbreak of Clostridium diffi cile-associated diarrhea with high morbidity and mortality . N Engl J Med 2005; 353 : 2442-9 .
2. Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, et al . Clostridium diffi cile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity . CMAJ 2004; 171 : 466-72 .
3. Fujitani S, George WL, Murthy A R. C omparison of clinical severity score indices for Clostridium diffi cile infection . Infect Control Hosp Epidemiol 2011; 32 : 220-8 .
4. Belmares J, Gerding DN, Parada JP, Miskevics S, Weaver F, Johnson S . Outcome of metronidazole therapy for Clostridium diffi cile disease and correlation with a scoring system . J Infect 2007; 55 : 495-501 .
5. Zar FA, Bakkanagari S R, Moorthi K M, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium diffi cile-associated diarrhea, stratifi ed by disease severity . Clin Infect Dis 2007; 45 : 302-7 .
6. V elazquez-Gomez I, Rocha-Rodriguez R, Toro DH, Gutierrez-Nunez JJ, Gonzalez G, Saavedra S. A severity score index for Clostridium diffi cile infection . Infect Dis Clin Pract 2008; 16 : 376-8 .
7. Lungulescu O A, Cao W, Gatskevich E, Tlhabano L, Stratidis JG . CSI: a severity index for Clostridium diffi cile infection at the time of admission . J Hosp Infect 2011; 79 : 151-4 .
8. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al . Clinical practice guidelines for Clostridium diffi cile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA) . Infect Control Hosp Epidemiol 2010; 31 : 431-55 .
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation . J Chronic Dis 1987; 40 : 373-83 .
10. Louie, T, Gerson, M, Grimmard, D, Johnson S, Poirier A, Weiss K, et al . Results of a phase III trial comparing tolevamer, vancomycin, and metronidazole in patients with Clostridium diffi cile-associated diarrhea (CDAD) . Program and Abstracts of the 47 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL : September 17-20, 2007; Abstract K-425a.
11. McGowan A P, Lalayiannis LC, Sarma JB, Marshall B, Martin KE, Welfare MR . Thirty-day mortality of Clostridium diffi cile infection in a UK National Health Service Foundation Trust between 2002 and 2008 . J Hosp Infect 2010; 77 : 11-5 .
12. Hota SS, Achonu C, Crowcroft NS, Harvey BJ, Lauwers A, Gardam MA . Determining mortality rates attributable to Clostridium diffi cile infection . Emerg Infect Dis 2012; 18 : 305-7 .
13. Kenneally C, Rosini J M, Skrupky L P, Doherty J A, Hollands JM, Martinez E, et al . Analysis of 30-day mortality for Clostridium diffi cile-associated disease in the ICU setting . Chest 2007; 132 : 418-24 .
14. Recommendations for preventing the spread of vancomycin resistance . Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC) . MMWR Recomm Rep 1995; 44 : 1-13
15. Al-Nassir WN, Sethi A K, Li Y, Pultz MJ, Riggs MM, Donskey CJ . Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium diffi cileassociated disease . Antimicrob Agents Chemother 2008; 52 : 2403-6 .
16. Miller M, Bernard L, Thompson M, Grima D, Pepin J . Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium diffi cile infection . Infect Control Hosp Epidemiol 2010; 31 : 710-5